Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies

Cancer Biology and Therapy

Volumn 16, Issue 5, 2015, Pages 790-798

  Chung, Thomas K ^a   Warram, Jason ^a   Day, Kristine E ^a   Hartman, Yolanda ^a   Rosenthal, Eben L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Anti angiogenesis therapy; Head and neck cancer; Monoclonal antibody therapy; Near infrared fluorescence; Optical imaging; Therapeutic delivery; Vessel normalization

Indexed keywords

BEVACIZUMAB; CD31 ANTIGEN; CETUXIMAB; FLUORESCENT DYE; IMMUNOGLOBULIN G; KI 67 ANTIGEN; PANITUMUMAB; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG UPTAKE; FLUORESCENCE; FLUORESCENCE IMAGING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NEAR INFRARED FLUORESCENCE IMAGING; NEAR INFRARED IMAGING SYSTEM; NONHUMAN; PERICYTE; TUMOR SPECIFIC UPTAKE; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; DISEASE MODEL; MOUTH NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BEVACIZUMAB; CELL LINE, TUMOR; CETUXIMAB; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, NUDE; MOUTH NEOPLASMS;

EID: 84943739421     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1016664     Document Type: Article

References (37)

1. Lee CM, Tannock IF. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer 2010; 10: 255; PMID: 20525277; http://dx. doi. org/10. 1186/1471-2407-10-255.
2. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-27; PMID: 21629292; http://dx. doi. org/10. 1038/nrd3455.
3. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92; PMID: 16862189; http://dx. doi. org/10. 1038/nrc1893.
4. Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, Larson SM, Keenan AM. The pharmacology of monoclonal antibodies. Ann N Y Acad Sci 1987; 507: 199-210; PMID: 3327413; http://dx. doi. org/10. 1111/j. 1749-6632. 1987. tb45802. x.
5. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res 2002; 62: 5381-5; PMID: 12235011.
6. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008; 456: 809-13; PMID: 18997771; http://dx. doi. org/10. 1038/nature07424.
7. Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harbor Perspect Med 2012; 2: a006486; PMID: 22393532; http://dx. doi. org/10. 1101/cshperspect. a006486.
8. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, van Oosterom AT. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88: 1979-86; PMID: 12799646; http://dx. doi. org/10. 1038/sj. bjc. 6601005.
9. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942-50; PMID: 17606728; http://dx. doi. org/10. 1158/1078-0432. CCR-07-0278.
10. Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 2012; 11: 752-62; PMID: 22222630; http://dx. doi. org/10. 1158/1535-7163. MCT-11-0742-T.
11. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-7; PMID: 17538161; http://dx. doi. org/10. 1200/JCO. 2006. 06. 7447.
12. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27; PMID: 18784101; http://dx. doi. org/10. 1056/NEJMoa0802656.
13. Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2866-72; PMID: 16717293; http://dx. doi. org/10. 1200/JCO. 2005. 04. 3547.
14. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 2001; 37, Supplement 4: 16-22; http://dx. doi. org/10. 1016/S0959-8049(01)00233-7.
15. Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, Kang X. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies 2010; 19: 89-99; PMID: 21178280.
16. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-31; PMID: 19410716; http://dx. doi. org/10. 1016/S0140-6736(09)60569-9.
17. Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 918-27; PMID: 20100958; http://dx. doi. org/10. 1200/JCO. 2009. 25. 2890.
18. Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broët P, Marmey B, Chauvenet L, Audouin J, Pujade-Lauraine E, et al. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer 2004; 91: 470-5; PMID: 15226774; http://dx. doi. org/10. 1038/sj. bjc. 6601961.
19. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309; PMID: 22276820; http://dx. doi. org/10. 1056/NEJMoa1111065.
20. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366: 310-20; PMID: 22276821; http://dx. doi. org/10. 1056/NEJMoa1111097.
21. Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013; 24: 2978-84; PMID: 24136883; http://dx. doi. org/10. 1093/annonc/mdt361.
22. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci 2012; 109: 17561-6; PMID: 23045683; http://dx. doi. org/10. 1073/pnas. 1215397109.
23. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen HX, Grandis JR, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2013; 24: 220-5; PMID: 22898037; http://dx. doi. org/10. 1093/annonc/mds245.
24. Zhang Q, Bindokas V, Shen J, Fan H, Hoffman RM, Xing HR. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents. Mol Cancer Ther 2011; 10: 1173-84; PMID: 21586628; http://dx. doi. org/10. 1158/1535-7163. MCT-11-0008.
25. Van der Veldt Astrid AM, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012; 21: 82-91; PMID: 22264790; http://dx. doi. org/10. 1016/j. ccr. 2011. 11. 023.
26. Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A 2013; 110: 18632-7; PMID: 24167277; http://dx. doi. org/10. 1073/pnas. 1318415110.
27. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011; 29: 4286-93; PMID: 21990397; http://dx. doi. org/10. 1200/JCO. 2010. 34. 1255.
28. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-60; PMID: 21383283; http://dx. doi. org/10. 1200/JCO. 2010. 28. 0982.
29. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-47; PMID: 20498403; http://dx. doi. org/10. 1200/JCO. 2008. 21. 6457.
30. Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, Timmer-Bosscha H, Lub-de Hooge MN, Schröder CP, de Vries EG. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 2013; 73: 3347-55; PMID: 23580572; http://dx. doi. org/10. 1158/0008-5472. CAN-12-3518.
31. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752-6; PMID: 7641188.
32. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998; 95: 4607-12; PMID: 9539785; http://dx. doi. org/10. 1073/pnas. 95. 8. 4607.
33. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJW, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-11; PMID: 15837620; http://dx. doi. org/10. 1016/j. ccr. 2005. 03. 003.
34. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009; 8: 2861-71; PMID: 19825804; http://dx. doi. org/10. 1158/1535-7163. MCT-09-0195.
35. Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nature Nanotechnol 2012; 7: 383-8; PMID: 22484912; http://dx. doi. org/10. 1038/nnano. 2012. 45.
36. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nuclear Med 1990; 31: 1191-8; PMID: 2362198.
37. Berk DA, Yuan F, Leunig M, Jain RK. Direct in vivo measurement of targeted binding in a human tumor xenograft. Proc Natl Acad Sci U S A 1997; 94: 1785-90; PMID: 9050856; http://dx. doi. org/10. 1073/pnas. 94. 5. 1785.